Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.12.23 | Akerna Corp. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
09.12.23 | AMERICAN SOFTWARE INC - 10-K/A, Annual Report | 3 | SEC Filings | ||
09.12.23 | AMERICAN SOFTWARE INC - 10-Q/A, Quarterly Report | 3 | SEC Filings | ||
09.12.23 | TREASURE GLOBAL INC - 8-K, Current Report | - | SEC Filings | ||
09.12.23 | Blue Star Foods Corp. - 8-K, Current Report | - | SEC Filings | ||
09.12.23 | TANDEM DIABETES CARE INC - 8-K, Current Report | - | SEC Filings | ||
09.12.23 | LGI Homes, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.12.23 | Visionary Education Technology Holdings Group Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
09.12.23 | URANIUM ENERGY CORP - 10-Q, Quarterly Report | 17 | SEC Filings | ||
09.12.23 | RICHTECH ROBOTICS INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
09.12.23 | LumiraDx Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
09.12.23 | Black Mountain Acquisition Corp. - 8-K, Current Report | - | SEC Filings | ||
09.12.23 | Central North Airport Group - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
09.12.23 | SU Group Holdings Ltd - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings | ||
09.12.23 | Biomea Fusion, Inc.: Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts | 205 | GlobeNewswire (Europe) | At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100... ► Artikel lesen | |
09.12.23 | FibroGen, Inc.: FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting | 326 | GlobeNewswire (Europe) | A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence = 56 days with roxadustat vs. placebo (36.1% vs... ► Artikel lesen | |
09.12.23 | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) | 210 | GlobeNewswire (Europe) | Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting =1 point improvement on PGIS by week 20 100% of bezuclastinib treated... ► Artikel lesen | |
09.12.23 | TScan Therapeutics, Inc.: TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition | 136 | GlobeNewswire (Europe) | No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention... ► Artikel lesen | |
09.12.23 | Century Therapeutics, Inc.: Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits | 146 | GlobeNewswire (Europe) | - Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient - - Preliminary... ► Artikel lesen | |
09.12.23 | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial | 194 | GlobeNewswire (Europe) | Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 1.750 |
BAYER | 1.496 |
NEL | 1.416 |
TUI | 1.284 |
PLUG POWER | 1.219 |
NOVAVAX | 1.199 |
SIEMENS ENERGY | 1.185 |
MERCEDES-BENZ | 1.152 |
PALANTIR TECHNOLOGIES | 818 |
NVIDIA | 769 |
ALLIANZ | 766 |
RWE | 734 |
DEUTSCHE BANK | 715 |
BYD | 676 |
BASF | 624 |
DEUTSCHE LUFTHANSA | 607 |
RHEINMETALL | 605 |
TESLA | 574 |
VOLKSWAGEN | 546 |
COMMERZBANK | 535 |
INFINEON | 535 |
NORDEX | 502 |
AIXTRON SE | 491 |
RENK GROUP | 481 |
STANDARD LITHIUM | 473 |